Stock Track | Avita Therapeutics Plummets 22.58% on CEO Change and Q3 Revenue Guidance

Stock Track

Oct 17, 2025

Shares of Avita Therapeutics (ASX:AVH) plummeted 22.58% in Friday's trading session following the announcement of a leadership change and preliminary third-quarter revenue guidance. The significant drop reflects investor concerns over the company's immediate future and financial performance.

The company disclosed in a filing with the Australian Securities Exchange that Chairman Cary Vance has been appointed as interim Chief Executive Officer, effective immediately. Vance succeeds Jim Corbett in this role, marking a notable shift in the company's leadership. Avita's board has stated its intention to engage an executive search firm to identify a permanent CEO, considering both internal and external candidates for the position.

Adding to investor unease, Avita Medical provided preliminary revenue guidance for the third quarter ended September 30, projecting revenues of approximately AU$17 million. This financial outlook, combined with the sudden leadership transition, appears to have sparked significant selling pressure on the stock, resulting in the sharp decline observed during Friday's trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125214991"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125214991\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125214991?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125214991","market":"hk","top_or_hot":-1,"title":"Stock Track | Avita Therapeutics Plummets 22.58% on CEO Change and Q3 Revenue Guidance","media":"Stock Track","content":"<p>Shares of Avita Therapeutics (ASX:AVH) plummeted 22.58% in Friday's trading session following the announcement of a leadership change and preliminary third-quarter revenue guidance. The significant drop reflects investor concerns over the company's immediate future and financial performance.</p>\n\n<p>The company disclosed in a filing with the Australian Securities Exchange that Chairman Cary Vance has been appointed as interim Chief Executive Officer, effective immediately. Vance succeeds Jim Corbett in this role, marking a notable shift in the company's leadership. Avita's board has stated its intention to engage an executive search firm to identify a permanent CEO, considering both internal and external candidates for the position.</p>\n\n<p>Adding to investor unease, Avita Medical provided preliminary revenue guidance for the third quarter ended September 30, projecting revenues of approximately AU$17 million. This financial outlook, combined with the sudden leadership transition, appears to have sparked significant selling pressure on the stock, resulting in the sharp decline observed during Friday's trading session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Avita Therapeutics Plummets 22.58% on CEO Change and Q3 Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Avita Therapeutics Plummets 22.58% on CEO Change and Q3 Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-17 07:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Avita Therapeutics (ASX:AVH) plummeted 22.58% in Friday's trading session following the announcement of a leadership change and preliminary third-quarter revenue guidance. The significant drop reflects investor concerns over the company's immediate future and financial performance.</p>\n\n<p>The company disclosed in a filing with the Australian Securities Exchange that Chairman Cary Vance has been appointed as interim Chief Executive Officer, effective immediately. Vance succeeds Jim Corbett in this role, marking a notable shift in the company's leadership. Avita's board has stated its intention to engage an executive search firm to identify a permanent CEO, considering both internal and external candidates for the position.</p>\n\n<p>Adding to investor unease, Avita Medical provided preliminary revenue guidance for the third quarter ended September 30, projecting revenues of approximately AU$17 million. This financial outlook, combined with the sudden leadership transition, appears to have sparked significant selling pressure on the stock, resulting in the sharp decline observed during Friday's trading session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVH.AU","symbol_name":"Avita Therapeutics","start_time":0,"source_url":"","article_id":"1125214991","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125214991","pubTimestamp":1760657293,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Avita Therapeutics (ASX:AVH) plummeted 22.58% in Friday's trading session following the announcement of a leadership change and preliminary third-quarter revenue guidance. The significant...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVH.AU":"Avita Therapeutics"},"translate_title":"个股追踪|CEO变更及Q3营收指引阿维塔治疗暴跌22.58%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVH.AU":1},"content_text":"Shares of Avita Therapeutics (ASX:AVH) plummeted 22.58% in Friday's trading session following the announcement of a leadership change and preliminary third-quarter revenue guidance. The significant drop reflects investor concerns over the company's immediate future and financial performance.\nThe company disclosed in a filing with the Australian Securities Exchange that Chairman Cary Vance has been appointed as interim Chief Executive Officer, effective immediately. Vance succeeds Jim Corbett in this role, marking a notable shift in the company's leadership. Avita's board has stated its intention to engage an executive search firm to identify a permanent CEO, considering both internal and external candidates for the position.\nAdding to investor unease, Avita Medical provided preliminary revenue guidance for the third quarter ended September 30, projecting revenues of approximately AU$17 million. This financial outlook, combined with the sudden leadership transition, appears to have sparked significant selling pressure on the stock, resulting in the sharp decline observed during Friday's trading session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}